Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iontophoresis of Iloprost and Treprostinil in Healthy Volunteers
NCT01082484Phase 2Completed
- Sponsor
- CHU Grenoble Alpes
- Start
- Jan 2010
- Primary completion
- Jan 2011
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of iloprost and treprostinil in Raynaud's phenomenon (RP) and systemic sclerosis (SSc), sponsored by CHU Grenoble Alpes. Primary endpoint: Amplitude of forearm cutaneous vasodilatation assessed using laser Doppler imaging at 24 hours. Started Jan 2010; status: completed.
02
Drugs
iloprosttreprostinil
03
Conditions
Raynaud's phenomenon (RP)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT01082484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01082484.